Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders
15 Février 2019 - 8:06PM
Amsterdam, The Netherlands, 15 February 2019 -
Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that it has convened an
extraordinary general meeting of shareholders ("EGM") to be held on
Friday 29 March 2019 at 10:00 am CET at the Amsterdam Stock
Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The
Netherlands.
The EGM will decide on the
following matters:
- The appointment of Scott Holmes
as a member of the Management Board;
- Proposals to amend the
remuneration policy for the Management Board and the remuneration
of the Supervisory Board, which includes the granting of
options;
- The delegation to the Management
Board of the authority to issue shares and grant rights to acquire
shares and to restrict or exclude pre-emptive rights;
- A proposed first amendment of the
articles of association to increase Kiadis Pharma's authorized
share capital; and
- A proposed second conditional
amendment of the articles of association to introduce preferred
shares such that Kiadis Pharma's authorized share capital will be
divided into ordinary shares and preferred shares, with the view of
enabling the Management Board and the Supervisory Board to
implement anti-takeover protection in the form of a call option to
subscribe for preferred shares that is granted to an independent
foundation the statutory goal of which is to protect the Company's
interests. This proposal to amend the articles of association
is conditional in the sense that if the EGM approves the amendment
and the notarial deed to amend the articles of association is
executed, the amendment will not become effective unless and until
the Management Board at any future moment decides, after having
obtained approval from the Supervisory Board, to have the amendment
enter into force by depositing a copy thereof at the Trade Register
of the Chamber of Commerce. Shareholders, employees and other
stakeholders benefit from stable and balanced decision-making in
the general meeting of shareholders. Kiadis Pharma believes that
the interests of its stakeholders are best served if the Management
Board and the Supervisory Board are empowered to create a preferred
share protection mechanism that is common amongst listed Dutch
companies. While there is no immediate reason for taking this
measure, Kiadis Pharma believes that it can strengthen its
negotiating position should this be necessary at any time in the
future.
The notice and agenda for the EGM
as well as the proxy form are available on the Investors' section
of the Kiadis Pharma website at:
http://www.kiadis.com/investors/shareholders-meetings/.
For more information, please
contact:
Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1 508 479 3480
a.sullivan@kiadis.com |
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com |
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical HSCT for adult blood
cancers to address key limitations of haploidentical HSCT, without
prophylactic immunosuppression and its associated morbidity and
mortality. Based on the positive results from the single dose Phase
II CR-AIR-007 study, the Company submitted a marketing
authorization application to the European Medicines Agency in April
2017 for approval of ATIR101 as an adjunctive treatment in
haploidentical HSCT for high risk adult hematological malignancies.
If the product is conditionally approved, Kiadis Pharma intends to
launch ATIR101 in selected countries in Europe through its own
commercial organization starting in the second half of 2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase III clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, or PTCy protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy designation from the FDA in September
2017, which provides benefits that are materially equivalent to a
breakthrough designation from the FDA. In addition, ATIR101 has
been granted multiple orphan Drug designations both in the European
Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire